Autologous hematopoietic stem cell therapy (YaKe Biotechnology)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAutologous hematopoietic stem cell therapy (YaKe Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionB-lymphocyte antigen CD19 stimulants
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNingbo Yake Biotechnology Co LtdZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A